eZono Launches Innovation for Faster Adoption of Ultrasound-Guided Anesthesia At DAC 2009
New touch screen based, portable ultrasound system for anesthesia accelerates users’ learning curve, reduces complexity and yet is more affordable
eZono Launches Innovation for Faster Adoption of Ultrasound-Guided Anesthesia At DAC 2009
Widespread adoption of ultrasound-guided regional anesthesia has been hampered by complex technology and high training barriers. At the Deutscher Anästhesiecongress in Leipzig eZono AG unveils the eZono™ 3000 , a novel ultrasound imaging solution that lowers these hurdles.
eZono™ 3000 is the first portable system designed for anesthesia applications from the ground up. Complexity is replaced by intuitive, context sensitive icon and gesture based control via a unique touch screen interface. Unprecedented processing power enhances imaging - all packed into a robust notebook form factor. eZono’s patented on-board training system, Cue Cards, revolutionizes the learning experience. Cue Cards’ break-through is to transform anesthetists’ 3D static anatomical understanding to 2D real time sono-anatomy using rich multimedia content like 3D models, videos and images for synchronized reference and workflow guidance. This helps anesthetists to train faster and increase nerve block effectiveness. Furthermore the system automatically loads pre-sets, most common used system preferences, for a chosen anaesthesia or vascular access application.
“We are proud to introduce essential new features, like our Cue Cards, but also a more affordable system. Achieved by combining leading-edge technology, close collaboration with practising clinicians, and a lean supply-chain” says Allan Dunbar, eZono’s Chief Executive Officer.
Ultrasound-guided regional anesthesia offers substantial advantages for patients and clinics
More regional anesthesia procedures replace general anesthesia due to reduced complications and thus increased patient satisfaction. Further, they are more cost effective for clinics due to faster through-put of patients. However, the key issue is to apply the anaesthetic around the nerve correctly in order to block the pain. Ultrasound imaging helps anesthetists not only to see the nerve but also to control the injection. “The usage of ultrasound is without doubt the most important development in regional anaesthesia and has the potential to revolutionize it” concludes associate professor Egbert Hüttemann, Klinikum Worms .
eZono™ 3000 helps to overcome the training, complexity and investment challenges
“Although ultrasound-guided anaesthesia is literally a no-brainer, still 80% of regional anaesthesia procedures in Germany are done ‘blindly’ – without ultrasound support.” adds Reno Popp, surgeon and eZono’s medical advisor. Unique training challenges and complexity have been so far the major barriers.
Complexity is reduced significantly due to eZono™ 3000’s 10”4 touch screen in combination with an icon-based user interface. Furthermore the system features a novel way to adjust contrast and depth with a wipe of a finger. Fast boot time of less than 20 seconds, long battery life of up to 2.5h, and the built-in multimedia patient record database including data transfer capability via USB stick add to eZono™ 3000’s benefits.
Traditional ultrasound has often been too expensive for anesthesia. Thus the eZono™ 3000 has been designed with budget pressures in mind. “Standard hardware makes the system more affordable than traditional ultrasound devices. On top, the system is future-proof as it allows further upgrades easily by plugging in a USB stick” concludes Allan Dunbar.
The eZono™ 3000 is available in EMEA starting May 2009.
About eZono AG
eZono is a different kind of ultrasound company, one that develops and produces its application-specific devices in Germany. eZono was founded in July 2004 and is located in Jena. Its diversified staff consists of 16 nations and is supported by more than 40 investors globally.
Summary
The just released eZono™ 3000 portable ultrasound system accelerates anesthetists' learning curve in regional anesthesia.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5958355&lang=en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact:
eZono AG
Andre Jaekel
+49 3641 876 1730
Press@eZono.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KIOXIA and Linus Media Group Set World Record for Pi Calculation19.5.2025 08:00:00 CEST | Press release
New GUINNESS WORLD RECORDS Title for Most Accurate Value of Pi - 300 Trillion Digits Calculated Using KIOXIA NVMe™ SSDs Kioxia Corporation, a world leader in memory solutions, today announced that it has collaborated with Linus Media Group, creator of Linus Tech Tips and other influential technology-focused YouTubeTM channels, to set a new GUINNESS WORLD RECORDS® title for the Most Accurate Value of Pi. A groundbreaking 300 trillion digits were calculated and have been officially verified and confirmed by Guinness World Records1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250518801709/en/ KIOXIA SSD The record-smashing computation was enabled by a high-performance storage cluster comprising 2.2 petabytes (PB)2 of 30.72 terabyte (TB) CM Series and 15.36 TB CD Series PCIe® NVMe™-based solid-state drives (SSDs) from KIOXIA. These SSDs were configured in a network-attached storage environment connected to a dual-CPU compute
NetApp Builds AI Infrastructure on NVIDIA AI Data Platform19.5.2025 08:00:00 CEST | Press release
Businesses using NetApp AIPod can accelerate AI agents and speed up retrieval of relevant information NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it is working with NVIDIA to support the NVIDIA AI Data Platform reference design in the NetApp AIPod solution to accelerate enterprise adoption of agentic AI. Powered by the robust and mature data management capabilities of NetApp ONTAP®, NetApp AIPod deployments built on the NVIDIA AI Data Platform will help businesses build secure, governed, and scalable AI data pipelines for retrieval-augmented generation (RAG) and inferencing, enabling organizations to harness the full potential of AI innovation. As businesses invest in AI to solve complex business challenges, they need intelligent data infrastructure that can remove the data silos that slow technical innovation. The most recent NetApp Data Complexity report found that 79 percent of tech and business leaders agree that unifying their data est
Fujirebio Receives Marketing Clearance for Lumipulse®G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease17.5.2025 08:58:00 CEST | Press release
—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearancefor Patients Being Assessed for Alzheimer’s Disease. ——Availability of Accurate, Accessible, Blood-Based Diagnostic Tests Will Aid in Development and Availability of More Effective Interventions for Alzheimer’s Disease — Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause
IFF Announces Pricing of Tender Offers For Certain Outstanding Series of Notes16.5.2025 23:17:00 CEST | Press release
IFF (NYSE: IFF) announced today the Total Consideration (as defined below) payable in connection with its previously announced tender offers to purchase for cash: (i) up to $1,100,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 1 Maximum Amount”), of its 1.230% Senior Notes due 2025 (the “2025 Notes”), 1.832% Senior Notes due 2027 (the “2027 Notes”), 4.450% Senior Notes due 2028 (the “2028 Notes”) and 2.300% Senior Notes due 2030 (the “2030 Notes” and collectively with the 2025 Notes, the 2027 Notes and the 2028 Notes, the “Pool 1 Notes”) and (ii) up to $900,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 2 Maximum Amount” and, together with the Amended Pool 1 Maximum Amount, the “Amended Maximum Amounts”), of its 3.268% Senior Notes due 2040 (the “2040 Notes”), 4.375% Senior Notes due 2047 (the “2047 Notes”), 5.000% Senior Notes due 2048 (the “2048 Notes”) and 3.468% Senior Notes due 2050 (the “2050
Origins Launches in the U.S. Amazon Premium Beauty Store16.5.2025 15:00:00 CEST | Press release
The brand brings its high-performance, clinically proven, nature-inspired skincare to Amazon shoppers Origins, with over 30 years of expertise in combining naturally-derived and scientifically crafted ingredients for powerful skincare, announced its official debut in the U.S. Amazon Premium Beauty store today. Origins will offer its iconic skincare and body care products along with giftable sets that are perfect for any occasion. Origins will now bring naturally-derived, effective beauty to Amazon customers nationwide with convenience and thoughtful gifting in mind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250516435958/en/ This launch marks a strategic step in Origins’ ongoing efforts to meet the evolving needs of skincare shoppers, seeking high-performance, conscious beauty on their favorite platforms. By expanding to the U.S. Amazon Premium Beauty store, Origins reinforces its commitment to delivering both efficacy a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom